Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00939276 · ClinicalTrials.gov registry record · Phase 3
Macular Edema Incidence/Severity Reduction With Nevanac
A Phase 3 study, sponsored by Alcon Research.
- Terminated
- Registry status
- Phase 3
- Development phase
- 175
- Enrollment target
NCT00939276 is a Phase 3 study that was terminated before completion, run by Alcon Research. The registered enrollment target is 175 participants.
The verdict
NCT00939276, a Phase 3 study, was terminated before completion, sponsored by Alcon Research.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 175 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate NEVANAC in patients with diabetic retinopathy who developed macular edema (ME) within 90 days following cataract surgery.
Interventions
- DRUG Nepafenac ophthalmic suspension, 0.1% (NEVANAC®)
- DRUG Nepafenac ophthalmic suspension vehicle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 175 participants |
| Start Date | 2009-08 |
| Est. Completion | 2011-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00939276
The ClinicalTrials.gov registry entry for NCT00939276 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 175 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alcon Research, which has 275 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nepafenac ophthalmic suspension, 0.1% (NEVANAC®) is the first listed.
NCT00939276 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00939276 about?
NCT00939276 is a clinical study titled "Macular Edema Incidence/Severity Reduction With Nevanac". The purpose of this study is to evaluate NEVANAC in patients with diabetic retinopathy who developed macular edema (ME) within 90 days following cataract surgery.
What is the current status of trial NCT00939276?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 175 participants. The study started on 2009-08. Estimated completion is 2011-08.
What interventions are being tested in trial NCT00939276?
The interventions under investigation include: Nepafenac ophthalmic suspension, 0.1% (NEVANAC®) (DRUG), Nepafenac ophthalmic suspension vehicle (DRUG).
Who is sponsoring clinical trial NCT00939276?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.